Aceragen
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15 Tw Alexander Dr Ste 418, Durham, Nort...Website
www.aceragen.comRevenue
$16.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Aceragen
Aceragen is a rare disease biopharmaceutical company. They address rare, orphan diseases that typically have no available treatment, and strive to develop novel therapies which can have a positive impact on the lives of patients and families. They are based in Research Triangle Park, North Carolina.Explore more
Popular SearchesAceragenAceragen IncAceragen AceragenIdera PharmaceuticalsSIC Code 28,283NAICS Code 32,325Show moreAceragen Org Chart
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aceragen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Aceragen has new funding data
Earning: See what the market has to say on Aceragen recently announced quarterly report
Product Launch: Get notified when Aceragen launches new products
Click to see if Aceragen had a recent Job posting/layoffs
Aceragen, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Aceragen has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Aceragen
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Aceragen is spiking on competitors!
Recommended Actions
Find VP level buyers at Aceragen
Find 2 more new buyers
Compare Similar Companies to Aceragen
Compare insights from companies similar to Aceragen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aceragen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aceragen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aceragen.
Aceragen financials insights
Gather financial insights about Aceragen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$16.5M
Stock Offering
$27.7M
2014
Stock Offering
$40M
2015
Stock Offering
$86.3M
2016
Stock Offering
$50M
2017
Stock Offering
$46.8M
2019
Share Placement
$97.7M
2020
Share Placement
$20.7M
Aceragen Tech Stack
A closer look at the technologies used by Aceragen
See more technologies
Most Recent Scoops
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Aceragen News & Media
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
DURHAM, N.C. and EXTON, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requiresAceragen Announces Recommendation of Data Monitoring Committee in Terra Study
DURHAM, N.C. and EXTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (Nasdaq: ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and hasIdera Pharmaceuticals Acquires Aceragen
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis
$45 million clinical program funded by the Defense Threat Reduction Agency. Trial initiates clinical development effort in support of ACG-701 as a treatment for multiple life-threatening orphan pulmonary diseases, including cystic fibrosis $45 million clinical program funded by the Defense Threat Reduction Agency. Trial initiates clinical development effort in support of ACG-701 as a treatment for multiple life-threatening orphan pulmonary diseases, including cystic fibrosis
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aceragen
Sign Up For FreeTo access detailed company insights
Aceragen is a rare disease biopharmaceutical company. They address rare, orphan diseases that typically have no available treatment, and strive to develop novel therapies which can have a positive impact on the lives of patients and families. They are based in Research Triangle Park, North Carolina.... Read More
